Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Juan Angel Fresno Vara"'
Autor:
Lucia Trilla-Fuertes, Guillermo Prado-Vazquez, Angelo Gámez-Pozo, Rocio Lopez-Vacas, Maria Isabel Lumbreras Herrera, Virtudes Soriano, Fernando Garicano, Maria Jose Lecumberri, Maria Rodriguez, Margarita Majem, Elisabeth Perez, Maria Gonzalez-Cao, Juana Oramas, Alejandra Magdaleno, Joaquin Fra, Alfonso Martin, Monica Corral, Teresa Puertolas, Juan Angel Fresno Vara, Enrique Espinosa
Publikováno v:
Cancer Research. 82:5416-5416
Background: Prediction of response to immunotherapy remains an unmet need in the field of advanced melanoma. Methods: Computational analyses, including probabilistic graphical models, sparse k-means, and consensus cluster, were used to characterize m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05d529f480afca1b478160c1657f261e
https://doi.org/10.1158/1538-7445.am2022-5416
https://doi.org/10.1158/1538-7445.am2022-5416
Autor:
Alvaro Pinto, Lucía Trilla-Fuertes, Jesus Miranda Poma, Naveen Vasudev, Eugenia García-Fernández, Rocio Lopez Vacas, Natalia Miranda, Michelle Wilson, Elena López-Camacho, Ana Pertejo, Maria Isabel Lumbreras-Herrera, Joanne C Brown, Andrea Zapater-Moros, Guillermo De Velasco, Daniel E. Castellano, María Pilar González-Peramato, Enrique Espinosa, Rosamonde Banks, Juan Angel Fresno-Vara, Angelo Gámez-Pozo
Publikováno v:
Journal of Clinical Oncology. 40:e16519-e16519
e16519 Background: Prognosis of localized clear cell renal cell carcinoma (ccRCC) patients is estimated by nomograms based on clinico-pathological factors. However, clinical guidelines do not recommend their use. Recently, pembrolizumab has demonstra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f97c803eb5eb3a8ea0830f6cbc93819
https://doi.org/10.1200/jco.2022.40.16_suppl.e16519
https://doi.org/10.1200/jco.2022.40.16_suppl.e16519
Autor:
Angelo Gámez-Pozo, Iker Sánchez-Navarro, Manuel Nistal, Enrique Calvo, Rosario Madero, Esther Díaz, Emilio Camafeita, Javier de Castro, Juan Antonio López, Manuel González-Barón, Enrique Espinosa, Juan Angel Fresno Vara
Publikováno v:
PLoS ONE, Vol 4, Iss 11, p e7731 (2009)
BACKGROUND:Proteomics is expected to play a key role in cancer biomarker discovery. Although it has become feasible to rapidly analyze proteins from crude cell extracts using mass spectrometry, complex sample composition hampers this type of measurem
Externí odkaz:
https://doaj.org/article/3758d45e9802400c8d8805be7f8c9549
Autor:
Enrique Espinosa, Iker Sánchez-Navarro, Angelo Gámez-Pozo, Alvaro Pinto Marin, David Hardisson, Rosario Madero, Andrés Redondo, Pilar Zamora, Belén San José Valiente, Marta Mendiola, Manuel González Barón, Juan Angel Fresno Vara
Publikováno v:
PLoS ONE, Vol 4, Iss 6, p e5911 (2009)
INTRODUCTION: Gene profiling may improve prognostic accuracy in patients with early breast cancer, but this technology is not widely available. We used commercial assays for qRT-PCR to assess the performance of the gene profiles included in the 70-Ge
Externí odkaz:
https://doaj.org/article/bd6fb78093714c29bc4d6a6a052b1ca5
Autor:
Marta Mendiola, Jorge Barriuso, Andrés Redondo, Adrián Mariño-Enríquez, Rosario Madero, Enrique Espinosa, Juan Angel Fresno Vara, Iker Sánchez-Navarro, Ginés Hernández-Cortes, Pilar Zamora, Elia Pérez-Fernández, María Miguel-Martín, Asunción Suárez, José Palacios, Manuel González-Barón, David Hardisson
Publikováno v:
PLoS ONE, Vol 3, Iss 12, p e4051 (2008)
BACKGROUND: Ovarian carcinoma is the most important cause of gynecological cancer-related mortality in Western societies. Despite the improved median overall survival in patients receiving chemotherapy regimens such as paclitaxel and carboplatin comb
Externí odkaz:
https://doaj.org/article/ea7e833d93d04d07873dba09f27b7498
Autor:
José Manuel, García-Martínez, Juan Angel, Fresno Vara, Pedro, Lastres, Carmelo, Bernabéu, Pablo Ortiz, Betés, Jorge, Martín-Pérez
Publikováno v:
Biochemical pharmacology. 65(2)
Metamizol is an analgesic and antipyretic agent that can induce agranulocytosis in certain patients. However, its effects on granulocyte viability and differentiation have been poorly evaluated. Here we analysed the effects of metamizol and its activ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ce273da430ea3c5be5ca74c5b46cdd61
https://pubmed.ncbi.nlm.nih.gov/12504796
https://pubmed.ncbi.nlm.nih.gov/12504796
Autor:
Angelo Gámez-Pozo, Juan Lucas Bayo Calero, Isabel Alvarez, Ana Santaballa, Juan Lao Romera, Xavier Gonzalez, Luis Manso, Pilar Zamora, Cesar Mendiola, Manuel Ruiz Borrego, Ruth Afonso Gomez, Jose Valero Alvarez Gallego, Carmen Crespo Massieu, J. Lopez, Francisco Javier Salvador Bofill, Gustavo Catalan, Ramon Perez-Carrion, Eva Maria Ciruelos Gil, Mireia Margeli Vila, Juan Angel Fresno-Vara
Publikováno v:
Web of Science
e11081 Background: Trastuzumab has shown an improvement in survival outcomes among patients with HER2+ metastatic breast cancer (MBC). Identification of factors and tumor molecular profiles that may predict long-term remission has become a key-issue.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a9875ad4e503b8d971d377da87cd8b3
https://doi.org/10.1200/jco.2012.30.15_suppl.e11081
https://doi.org/10.1200/jco.2012.30.15_suppl.e11081
Publikováno v:
Immunotherapy Weekly; 9/19/2023, p2469-2469, 1p
Publikováno v:
Immunotherapy Weekly; 2/28/2023, p1012-1012, 1p
Publikováno v:
Cancer Weekly; 11/12/2024, p746-746, 1p